for the Molecular and Cellular Immunology Core As the singular research resource for flow cytometry, cell sorting and myriad immunological services at the University of Hawaii (UH) and in the entire State of Hawaii, the Molecular and Cellular Immunology (MCI) Core has had a significant impact on increasing research productivity, enhancing research competitiveness and heightening grants success during COBRE Phases I and II. Extramurally funded research is heavily dependent on the MCI Core, and the need is anticipated to grow during and beyond the Phase III COBRE period. The Phase III COBRE objective of facilitating the transition of the MCI Core into a sustainable state-of-the-art core facility capable of supporting high-caliber research on new, emerging and re-emerging infectious diseases, as well as other fields of scientific inquiry, will be achieved by (1) enhancing and streamlining core operations; (2) growing and diversifying the user base, capability, capacity and reach; and (3) strengthening the core infrastructure.
For Aim 1, needs assessments and user satisfaction surveys will be conducted to ensure efficiency and effectiveness of core operations. Also, mentoring and training of current and prospective users will be better integrated, and partnerships will be formed with research training programs in infectious diseases and immunology.
For Aim 2, outreach and marketing activities will be expanded to other local academic institutions, biotech companies and hospitals beyond the UH System, and strong partnerships will be formed with similar cores located in other COBRE, INBRE and IDeA-CTR programs to grow and diversify the core user base and to acquire new tools and techniques. Also, the MCI Core will leverage the existing infrastructure of research training laboratories in the Asia-Pacific region to facilitate international collaborative research. And for Aim 3, sustainability and phased-in business plans will be developed during the Phase III COBRE period to draw on multiple avenues of intramural and extramural support to sustain the Core. Periodic evaluation and review of the Core's fiscal health will allow necessary restructuring of the key elements affecting solvency to guide efforts to sustain the Core beyond Phase III COBRE support. The MCI Core is expected to achieve each of the above-stated specific aims. A strong commitment of $50,000 per year for five years beyond the Phase III COBRE period, by the JABSOM Dean, will provide an important hedge against uncertain revenue streams during this competitive and uncertain funding climate and will ensure continued core operations, with the prospect of increased grants success and core sustainability.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
5P30GM114737-05
Application #
9735372
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
2021-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Hawaii
Department
Type
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Dou, Yuhong; Zhu, Yong; Ai, Junmei et al. (2018) Plasma small ncRNA pair panels as novel biomarkers for early-stage lung adenocarcinoma screening. BMC Genomics 19:545
To, Albert; Medina, Liana O; Mfuh, Kenji O et al. (2018) Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice. mSphere 3:
Medina, Liana O; To, Albert; Lieberman, Michael M et al. (2018) A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates. Front Immunol 9:2464
D'Antoni, Michelle L; Mitchell, Brooks I; McCurdy, Sara et al. (2018) Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol 104:1241-1252
Marciel, Michael P; Rose, Aaron H; Martinez, Verena et al. (2018) Calpain-2 inhibitor treatment preferentially reduces tumor progression for human colon cancer cells expressing highest levels of this enzyme. Cancer Med 7:175-183
Abanda, N N; DjieugouƩ, J Y; Khadka, V S et al. (2018) Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations. Clin Microbiol Infect 24:781.e1-781.e3
Guo, Mengjie; Lu, Sicheng; Huang, Hongming et al. (2018) Increased AURKA promotes cell proliferation and predicts poor prognosis in bladder cancer. BMC Syst Biol 12:118
Hynson, Nicole A; Frank, Kiana L; Alegado, Rosanna A et al. (2018) Synergy among Microbiota and Their Hosts: Leveraging the Hawaiian Archipelago and Local Collaborative Networks To Address Pressing Questions in Microbiome Research. mSystems 3:
Hu, Ling; Zhang, Rong; Yuan, Qiong et al. (2018) The emerging role of microRNA-4487/6845-3p in Alzheimer's disease pathologies is induced by A?25-35 triggered in SH-SY5Y cell. BMC Syst Biol 12:119
Jiang, Zhenhuan; Jiang, Jiannong; Zhao, Bizeng et al. (2018) CPNE1 silencing inhibits the proliferation, invasion and migration of human osteosarcoma cells. Oncol Rep 39:643-650

Showing the most recent 10 out of 65 publications